Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR.
- Author:
Hyung Seok PARK
1
;
Hyun Ju HAN
;
Soohyeon LEE
;
Gun Min KIM
;
Seho PARK
;
Yeon A CHOI
;
Jeong Dong LEE
;
Gi Moon KIM
;
Joohyuk SOHN
;
Seung Il KIM
Author Information
- Publication Type:Original Article
- Keywords: Cytokeratin-19 mRNA; circulating tumor cells; RT-PCR; peripheral blood samples; metastatic breast cancer
- MeSH: Biomarkers, Tumor/*blood; Breast Neoplasms/blood/*pathology; Female; Humans; Keratin-19/*blood/genetics; *Neoplastic Cells, Circulating; Prognosis; Prospective Studies; RNA, Messenger/*blood; Real-Time Polymerase Chain Reaction; *Reverse Transcriptase Polymerase Chain Reaction/methods
- From:Yonsei Medical Journal 2017;58(1):19-26
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The roles of circulating tumor cells (CTCs) as predictive and prognostic factors, as well as key mediators in the metastatic cascade, have been investigated. This study aimed to validate a method to quantify CTCs in peripheral blood using a real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay for cytokeratin (CK)-19 and to evaluate the utility of this assay in detecting CTCs in breast cancer patients. MATERIALS AND METHODS: Real-time monitoring PCR of fluorescently labeled specific hybridization probes for CK-19 mRNA was established. Peripheral blood samples from 30 healthy donors, 69 patients with early breast cancer, 47 patients with locally advanced breast cancer, and 126 patients with metastatic breast cancer were prospectively obtained and analyzed for CTC detection. RESULTS: CK-19 mRNA was not detectable in healthy subjects using the real-time RT-PCR method. The detection rates of CK-19 mRNA in breast cancer patients were 47.8% for early breast cancer (33/69), 46.8% for locally advanced breast cancer (22/47), and 61.1% for metastatic breast cancer (77/129). The detection rate of CK-19-positive CTCs in metastatic disease was slightly higher than early or locally advanced breast cancer; however, the detection rate according to disease burden was not statistically different (p=0.097). The detection rate was higher in patients with pleural metastasis (p=0.045). CTC detection was associated with poor survival (p=0.014). CONCLUSION: A highly specific and sensitive CK-19 mRNA-based method to detect CTCs in peripheral blood in breast cancer patients can be used in further prospective studies to evaluate the predictive and prognostic importance of CTCs.
